Advertisement
UK markets close in 1 hour 52 minutes

  • FTSE 100

    8,123.09
    +44.23 (+0.55%)
     

  • FTSE 250

    19,785.44
    +183.46 (+0.94%)
     

  • AIM

    755.27
    +2.15 (+0.29%)
     

  • GBP/EUR

    1.1669
    +0.0013 (+0.11%)
     

  • GBP/USD

    1.2511
    -0.0000 (-0.00%)
     

  • Bitcoin GBP

    51,106.95
    +598.60 (+1.19%)
     

  • CMC Crypto 200

    1,378.62
    -17.92 (-1.28%)
     

  • S&P 500

    5,083.75
    +35.33 (+0.70%)
     

  • DOW

    38,136.57
    +50.77 (+0.13%)
     

  • CRUDE OIL

    84.36
    +0.79 (+0.95%)
     

  • GOLD FUTURES

    2,355.70
    +13.20 (+0.56%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,086.60
    +169.32 (+0.95%)
     

  • CAC 40

    8,062.50
    +45.85 (+0.57%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Is AbbVie (ABBV) Stock a Solid Choice Right Now?

Zacks Equity Research
·2-min read

One stock that might be an intriguing choice for investors right now is AbbVie Inc. ABBV. This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Large Cap Pharmaceuticals space as it currently has a Zacks Industry Rank of 12 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, AbbVie is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

AbbVie Inc. Price and Consensus

AbbVie Inc. Price and Consensus
AbbVie Inc. Price and Consensus

AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote

ADVERTISEMENT

In fact, over the past month, current quarter estimates have risen from $2.13 per share to $2.33 per share, while current year estimates have risen from $9.22 per share to $10.71 per share. This has helped ABBV to earn a zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider AbbVie. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AbbVie Inc. (ABBV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research